GLOBAL TRENDS IN PHARMACOGENOMICS INTEGRATION INTO CLINICAL PRACTICE: AN ARTICLE REVIEW
Keywords
Global Trends, Pharmacogenomics Integration, Clinical ChatbotAbstract
Introduction: The integration of pharmacogenomics into clinical practice offers great potential to transform conventional (trial-and-error) healthcare into preventive precision medicine, with the aim of minimizing treatment failure and adverse drug reactions. However, its global implementation still exhibits significant multidimensional disparities. Methods: This review article was compiled using a systematic narrative literature review of global scientific literature published through 2026 via the PubMed, Scopus, ScienceDirect, and Google Scholar databases. Results: Clinical standardization is dominated by international guidelines (CPIC and DPWG) as well as drug labeling policies from the FDA and EMA. Oncology is the most progressive sector in mandating pre-treatment genetic screening due to narrow therapeutic indices. Successful implementation in developed countries is supported by the digitization of genomic data integrated into Electronic Health Record (EHR) and Clinical Decision Support System (CDSS) systems. Nevertheless, adoption in developing countries remains hindered by high costs, limited insurance coverage, a lack of medical practitioner competency due to curriculum limitations, and the presence of a Caucasian population bias (genomic Eurocentrism) in global databases. Conclusion: Accelerating the widespread adoption of precision medicine requires a strategic shift from reactive testing to more cost-effective, preemptive preventive testing. Additionally, autonomous management of local genomic databases is necessary to eliminate ethnic bias, and interprofessional collaboration must be strengthened by positioning clinical pharmacists specializing in pharmacogenomics as key translational bridges to ensure patient safety.
References
[1] Abdela, O., Bhagavathula, A. S., Gebreyohannes, E. A., & Tegegn, H. (2017). Ethiopian health care professionals’ knowledge, attitude, and interests toward pharmacogenomics. Pharmacogenomics and Personalized Medicine, Volume 10, 279–285. https://doi.org/10.2147/PGPM.S145336
[2] Alhaddad, Z. A., AlMousa, H. A., & Younis, N. S. (2022). Pharmacists’ Knowledge, and Insights in Implementing Pharmacogenomics in Saudi Arabia. International Journal of Environmental Research and Public Health, 19(16), 10073. https://doi.org/10.3390/ijerph191610073
[3] Alnaimi, S. J., Ajaj, F., Awaisu, A., Alhathal, T., Mohammed, S., & Alhail, M. (2024). Assessment of knowledge, perceptions, and readiness of healthcare professionals towards clinical pharmacogenomics implementation in Qatar: a mixed-method study. Journal of Pharmaceutical Policy and Practice, 17(1). https://doi.org/10.1080/20523211.2024.2429785
[4] Bank, P., Caudle, K., Swen, J., Gammal, R., Whirl‐Carrillo, M., Klein, T., Relling, M., & Guchelaar, H. (2018). Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clinical Pharmacology & Therapeutics, 103(4), 599–618. https://doi.org/10.1002/cpt.762
[5] Cacabelos, R., Cacabelos, N., & Carril, J. C. (2019). The role of pharmacogenomics in adverse drug reactions. Expert Review of Clinical Pharmacology, 12(5), 407–442. https://doi.org/10.1080/17512433.2019.1597706
[6] Cavallari, L. H., Cicali, E. J., Norris, M., Nguyen, K. A., & Duarte, J. D. (2025). Genotype-guided pharmacotherapy: the challenges of integrating pharmacogenomic testing into routine healthcare with a focus on experiences at a single site. Expert Review of Clinical Pharmacology, 18(9), 655–667. https://doi.org/10.1080/17512433.2025.2568089
[7] Chang, C., Too, C., Murad, S., & Hussein, S. H. (2011). Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population. International Journal of Dermatology, 50(2), 221–224. https://doi.org/10.1111/j.1365-4632.2010.04745.x
[8] Devi, K. (2018). The association of HLA B*15:02 allele and Stevens–Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population. International Journal of Dermatology, 57(1), 70–73. https://doi.org/10.1111/ijd.13812
[9] Fineide, M. J., Håvold, O. K. S., & Wenstøb, B. M. M. (2023). "Does One Size Fit All? - People’s expectations of future health and welfare services ". International Journal of Integrated Care, 23(S1), 680. https://doi.org/10.5334/ijic.ICIC23594
[10] Gastmeier, P. (2020). From ‘one size fits all’ to personalized infection prevention. Journal of Hospital Infection, 104(3), 256–260. https://doi.org/10.1016/j.jhin.2019.12.010
[11] Gawronski, B. E., Salloum, R. G., & Duarte, J. D. (2024). Estimating preferences and willingness to pay for pharmacogenetic testing in populations who are medically underserved: a discrete choice experiment. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1384667
[12] Graham, S. E., Clarke, S. L., Wu, K.-H. H., Kanoni, S., Zajac, G. J. M., Ramdas, S., Surakka, I., Ntalla, I., Vedantam, S., Winkler, T. W., Locke, A. E., Marouli, E., Hwang, M. Y., Han, S., Narita, A., Choudhury, A., Bentley, A. R., Ekoru, K., Verma, A., … Willer, C. J. (2021). The power of genetic diversity in genome-wide association studies of lipids. Nature, 600(7890), 675–679. https://doi.org/10.1038/s41586-021-04064-3
[13] Ju, D., Hui, D., Hammond, D. A., Wonkam, A., & Tishkoff, S. A. (2022). Importance of Including Non-European Populations in Large Human Genetic Studies to Enhance Precision Medicine. Annual Review of Biomedical Data Science, 5(1), 321–339. https://doi.org/10.1146/annurev-biodatasci-122220-112550
[14] Kim, J. A., Ceccarelli, R., & Lu, C. Y. (2021). Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020). Journal of Personalized Medicine, 11(3), 179. https://doi.org/10.3390/jpm11030179
[15] Koufaki, M.-I., Patrinos, G. P., & Vasileiou, K. Z. (2024). A qualitative approach to assess the opinion of physicians about the challenges and prospects of pharmacogenomic testing implementation in clinical practice in Greece. Human Genomics, 18(1), 82. https://doi.org/10.1186/s40246-024-00648-y
[16] Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., Kisor, D. F., Limdi, N. A., Lee, Y. M., Scott, S. A., Hulot, J., Roden, D. M., Gaedigk, A., Caudle, K. E., Klein, T. E., Johnson, J. A., & Shuldiner, A. R. (2022). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology & Therapeutics, 112(5), 959–967. https://doi.org/10.1002/cpt.2526
[17] Lemke, L. K., Alam, B., Williams, R., Starostik, P., Cavallari, L. H., Cicali, E. J., & Wiisanen, K. (2023). Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1179364
[18] Liu, M., Vnencak‐Jones, C. L., Roland, B. P., Gatto, C. L., Mathe, J. L., Just, S. L., Peterson, J. F., Van Driest, S. L., & Weitkamp, A. O. (2021). A Tutorial for Pharmacogenomics Implementation Through End‐to‐End Clinical Decision Support Based on Ten Years of Experience from PREDICT. Clinical Pharmacology & Therapeutics, 109(1), 101–115. https://doi.org/10.1002/cpt.2079
[19] Maillard, M., Schwab, M., Whirl‐Carrillo, M., Moyer, A. M., Suarez‐Kurtz, G., Pui, C., Stein, C. M., Klein, T. E., Spahn, C., Kwon, S., Hartono, J. L., de Boer, N. K., Ahmad, T., Antillon‐Klussmann, F. G., Caudle, K. E., Kato, M., Yeoh, A. E. J., Schmiegelow, K., & Yang, J. J. (2026). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. Clinical Pharmacology & Therapeutics, 119(4), 916–927. https://doi.org/10.1002/cpt.70209
[20] Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D., & Benbow, A. (2008). HLA-B*5701 Screening for Hypersensitivity to Abacavir. New England Journal of Medicine, 358(6), 568–579. https://doi.org/10.1056/NEJMoa0706135
[21] Morris, S. A., Nguyen, D. G., Morris, V., Mroz, K., Kwange, S. O., & Patel, J. N. (2024). Integrating pharmacogenomic results in the electronic health record to facilitate precision medicine at a large multisite health system. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 7(8), 845–857. https://doi.org/10.1002/jac5.1996
[22] Muller-Gass, A., Mukerjee, G., Dorfman, R., & Jetly, R. (2025). Implementation of Pharmacogenomics Testing in Daily Clinical Practice: Perspectives of Prescribers from Two Canadian Armed Forces Medical Clinics. Journal of Personalized Medicine, 15(3), 101. https://doi.org/10.3390/jpm15030101
[23] Peruzzi, E., Roncato, R., De Mattia, E., Bignucolo, A., Swen, J. J., Guchelaar, H., Toffoli, G., & Cecchin, E. (2025). Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? British Journal of Clinical Pharmacology, 91(2), 270–282. https://doi.org/10.1111/bcp.15956
[24] Pirmohamed, M. (2023). Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics, 24(6), 350–362. https://doi.org/10.1038/s41576-022-00572-8
[25] Schoeler, T., Speed, D., Porcu, E., Pirastu, N., Pingault, J.-B., & Kutalik, Z. (2023). Participation bias in the UK Biobank distorts genetic associations and downstream analyses. Nature Human Behaviour, 7(7), 1216–1227. https://doi.org/10.1038/s41562-023-01579-9
[26] Skokou, M., Karamperis, K., Koufaki, M.-I., Tsermpini, E.-E., Pandi, M.-T., Siamoglou, S., Ferentinos, P., Bartsakoulia, M., Katsila, T., Mitropoulou, C., Patrinos, G. P., Assimakopoulos, K., Georgila, E., Gourzis, P., Karaivazoglou, A., Prodromaki, O., Rigas, G., Voukelatou, G., Zacharopoulou, V., … Vozikis, A. (2024). Clinical implementation of preemptive pharmacogenomics in psychiatry. EBioMedicine, 101, 105009. https://doi.org/10.1016/j.ebiom.2024.105009
[27] Small, C. B., Margolis, D. A., Shaefer, M. S., & Ross, L. L. (2017). HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC Infectious Diseases, 17(1), 256. https://doi.org/10.1186/s12879-017-2331-y
[28] Stocker, S. L., & Polasek, T. M. (2025). Using pharmacogenomics to personalise drug therapy: which drugs, when and how. Australian Prescriber, 48(3), 82–86. https://doi.org/10.18773/austprescr.2025.021
[29] Swen, J. J., van der Wouden, C. H., Manson, L. E., Abdullah-Koolmees, H., Blagec, K., Blagus, T., Böhringer, S., Cambon-Thomsen, A., Cecchin, E., Cheung, K.-C., Deneer, V. H., Dupui, M., Ingelman-Sundberg, M., Jonsson, S., Joefield-Roka, C., Just, K. S., Karlsson, M. O., Konta, L., Koopmann, R., … Rajasingam, A. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet, 401(10374), 347–356. https://doi.org/10.1016/S0140-6736(22)01841-4
[30] Unertl, K. M., Jaffa, H., Field, J. R., Price, L., & Peterson, J. F. (2015). Clinician Perspectives on Using Pharmacogenomics in Clinical Practice. Personalized Medicine, 12(4), 339–347. https://doi.org/10.2217/PME.15.10
[31] Vos, C. F., ter Hark, S. E., Schellekens, A. F. A., Spijker, J., van der Meij, A., Grotenhuis, A. J., Mihaescu, R., Kievit, W., Donders, R., Aarnoutse, R. E., Coenen, M. J. H., & Janzing, J. G. E. (2023). Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder. JAMA Network Open, 6(5), e2312443. https://doi.org/10.1001/jamanetworkopen.2023.12443
[32] Walker, G. J., Harrison, J. W., Heap, G. A., Voskuil, M. D., Andersen, V., Anderson, C. A., Ananthakrishnan, A. N., Barrett, J. C., Beaugerie, L., Bewshea, C. M., Cole, A. T., Cummings, F. R., Daly, M. J., Ellul, P., Fedorak, R. N., Festen, E. A. M., Florin, T. H., Gaya, D. R., Halfvarson, J., … Ahmad, T. (2019). Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA, 321(8), 773. https://doi.org/10.1001/jama.2019.0709
[33] Wojcik, G. L., Graff, M., Nishimura, K. K., Tao, R., Haessler, J., Gignoux, C. R., Highland, H. M., Patel, Y. M., Sorokin, E. P., Avery, C. L., Belbin, G. M., Bien, S. A., Cheng, I., Cullina, S., Hodonsky, C. J., Hu, Y., Huckins, L. M., Jeff, J., Justice, A. E., … Carlson, C. S. (2019). Genetic analyses of diverse populations improves discovery for complex traits. Nature, 570(7762), 514–518. https://doi.org/10.1038/s41586-019-1310-4
[34] Wong, E., Bertin, N., Hebrard, M., Tirado-Magallanes, R., Bellis, C., Lim, W. K., Chua, C. Y., Tong, P. M. L., Chua, R., Mak, K., Lim, T. M., Cheong, W. Y., Thien, K. E., Goh, K. T., Chai, J.-F., Lee, J., Sung, J. J.-Y., Wong, T. Y., Chin, C. W. L., … Tan, P. (2023). The Singapore National Precision Medicine Strategy. Nature Genetics, 55(2), 178–186. https://doi.org/10.1038/s41588-022-01274-x
